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The incidence of gliomas is on the increase, according to epidemiological data. This increase is a conundrum because the brain
is in a privileged protected site behind the blood-brain barrier, and therefore partially buﬀered from environmental factors. In
addition the brain also has a very low proliferative potential compared with other parts of the body. Recent advances in neural
stem cell biology have impacted on our understanding of CNS carcinogenesis and tumor types. This article considers the cancer
stem cell theory with regard to CNS cancers, whether CNS tumors arise from human neural stem cells and whether glioma stem
cells can be reprogrammed.
1.Introduction
Epidemiological data suggests that the incidence of
gliomas—the most common form of intrinsic brain
tumour—is rising [1–3]. This is surprising, because the
brain is partially protected from the environment factors by
the blood-brain barrier and has a low proliferative potential
compared with other organs. Recent advances from the
stem-cell biology ﬁeld have impacted on our understanding
of CNS carcinogenesis and tumor types [4–7]. This paper
considers the evidence for the cancer stem cell theory,
whether CNS tumours arise from human neural stem cells
and whether glioma stem cells can be reprogrammed.
2.CancerStem-CellTheory
Normalhuman neuralstem cells are thoughtto residewithin
the brain mostly in the subventricular zone (SVZ) lining
the lateral ventricles and within the dentate gyrus of the
hippocampus [8, 9]. These stem cells persist throughout
adulthood into old age and may divide symmetrically
for self-renewal and asymmetrically to produce neurons,
astrocytes, and oligodendrocytes [10]. By comparison, brain
cancer or glioma stem cells are a population within a
glioma that can divide inﬁnitely, have the capacity to show
neuronal, astrocytic, and oligodendroglial diﬀerentiation
and can recapitulate the whole tumour when transplanted
into the brain of a nude mouse [11–13]. Whether brain
cancer stem cells actually develop from preexisting human
neural stem cells or represent cells which reacquire a stem-
like state as a by product of tumorigenesis or in vitro
culture conditions remains controversial [11–13]. Brain
cancer/glioma stem cells are of great interest, because they
may represent the population of cells within a tumour that
may be resistant to therapy and responsible for tumour
relapse.
Cancer stem cells, were originally described in acute
myeloid leukaemia and in haematological malignancies and
subsequently in many solid tumours [4, 6, 7]. Brain cancer
stem cells, also termed brain tumour-initiating cells were
ﬁrst described by groups who used CD133 to isolate a
population of brain tumour initiating or stem cells within
glioblastoma, the most aggressive primary brain tumour
[12, 14, 15]. The precise function of CD133, also known
as prominin, remains unclear; however, it was originally
shown to be a haemopoietic stem-cell marker [10]. Original
papers suggested that CD133-positive stem-like cells were
the only subpopulation of cells within the glioblastoma that
were capable of producing tumours when transplanted into
the brain of immunodeﬁcient mice [12, 14]. More recent
studies suggest that this may not always be the case and that
CD133 is not a speciﬁc marker for brain tumour-initiating2 Pathology Research International
cells or cancer stem-cells within glioma [15]. Therefore
many experimental diﬃculties still revolve around the lack
of speciﬁc glioma stem cell markers.
The question whether there is a universal glioma cancer
stem cell or whether diﬀerent subtypes of glioma contain
diﬀerent stem cells remains unanswered. Gilbertston’s group
suggest that the stem cell may vary according to the nature
of the original tumour [16]. He has shown that subtypes
of a diﬀerent type of glial tumour (ependymoma) may
derive from radial glia at diﬀerent locations at diﬀerent
stages of development in the nervous system. It is possible
that radial glia may represent the stem cell of ependy-
momas [17]. These cells express CD133, RC2, and nestin,
which are present on radial glia and human neural stem
cells.
In addition glioma stem cells are dependent on their
microenvironment in ordertomaintain stem-cell properties.
There is evidence to suggest that endothelial cells interact
and secrete factors in vitro that maintain a stem-like state
[17]. Increasing the number of endothelial cells expands
the population of self-renewing cells and their tumorigenic
properties. It is therefore possible that stem-like cells survive
within a vascular niche [17].
3.DoCNS TumoursArisefrom
HumanNeuralStemCells?
It is diﬃcult to determine whether CNS tumours arise
from human neural stem cells because of the diﬃculties
targeting these cells and the lack of robust stem-cell markers.
Recent work suggests that diﬀerent combinations of genetic
mutationsin the adult mouse subventricular zone determine
diﬀerent brain tumour phenotypes [18, 19]. The SVZ is a
well-described niche containing stem cells (type B cells),
transient amplifying precursors which derive from them
(type C cells), and neuroblasts (type A cells) [20, 21]. Many
studies use a GFAP-cre-mediated approach in transgenic
mice to target type B stem cells expressing GFAP and
subsequent progenitors expressing Nestin during develop-
ment. One intriguing study has shown that stimulation
of the PDGFR alpha expressing B-type neural stem cells
induces the formation of hyperplasia-resembling oligoden-
drogliomas next to the SVZ [22], which regresses after the
withdrawal of the growth factor. Similar approaches have
shown that the inactivation of various combinationsofother
tumour suppressor genes forms malignant astrocytomas
in the developing mouse brain SVZ. The inactivation of
Nf1 and p53 in neural stem/progenitor cells of the SVZ
and the inactivation of PTEN and p53 in progenitor cells
result in the formation of malignant astrocytomas [23, 24].
Other studies have shown that the activation of oncogenes
Ras and Akt in nestin-expressing progenitors (but not
in GFAP-expressing SVZ stem cells) induces glioblastoma
[25]. Similarly, nestin-expressing GFAP-negative progeni-
tor cells deﬁcient in INK4a/ARF and Bmi1, isolated in
vitro, can give rise to low-grade diﬀuse astrocytomas
[26].
Experiments in the adult SVZ have used a similar cre-lox
methodintransgenicmice.Theinactivationofcombinations
of Nf1 and p53, or Nf1, p53 and PTEN, in Nestin expressing
cells results in the formation of malignant gliomas [27, 28].
An interesting study combining the inactivation of Rb and
p53 in GFAP-expressing cells of the adult subventricular
zone resulted in the formation of primitive neuroectodermal
tumours (PNET) rather than gliomas, suggesting that the
inactivation of Rb may be key in determining this tumour
phenotype [17].
Although these experimental models are compelling evi-
denceforthe developmentofbrain cancersfrom neuralstem
cells, there are several reports indicating that transformed
mature astrocytes outside the SVZ can form gliomas given
appropriatemutations[29–33].Thisiscoupledwiththeclin-
icalobservationofgliomaoccurrenceinlocationsoutsidethe
traditional stem-cell compartments, and therefore the jury is
still outonwhether all CNStumorsarise fromhumanneural
stem cells.
4.CanWe Reprogramme GliomaStemCells?
A major conceptual advance in stem-cell biology ﬁeld
revolves around the work by Takahashi et al. [34]. Yana-
maka “reprogrammed” mature skin ﬁbroblasts into induced
pluripotent stem cells, commonly abbreviated as iPS cells or
iPSCs with four factors: Oct4, klf4, sox 2, and c-myc using a
retroviral aproach [34]. These iPS cells are similar to natural
pluripotent stem cells, such as embryonic stem cells because
they have the potential to be diﬀerentiated into diﬀerent cell
typessuchasnerveorcardiaccells.Thisadvancetheoretically
allows researchers to obtain pluripotent stem cells from skin
or other mature tissues without the controversial use of
embryos. It also avoids immune rejection because the cells
could be derived entirely from the individual patient to be
treated.
More fundamentally, it demonstrates the inﬂuence of
epigenetics in deciding the phenotype of an individual cell,
and raises the possibility that epigenetics could be used to
alter cell fate. Initial concerns about the risk of malignancy
in reprogrammed human neural stem cells have revolved
around the use of c-myc and viral transduction techniques.
These have been addressed by using alternative techniques
including the 2iIPS system [35], piggy bac transposons [36]
a n dp r o t e i nb a s e da p p r o a c h e s[ 37, 38]. In the CNS tumour
ﬁeld it has been shown both in vivo and in vitro that it is
possible to make certain types of glioma-initiating stem cells
diﬀerentiate into neuronal type cells using manipulation of
the Bone Morphogenetic Protein (BMP) pathway, which is
involved in diﬀerentiation of human embryonic stem cells
to neural stem cells [39, 40]. These studies demonstrated
am a j o rd i ﬀerentiation block in a subset of glioblastoma is
causedbythePolycombrepressorcomplex-(PRC-)mediated
epigenetic silencing of the BMPR1B promoter analogous to
early embryonic neural stem cells.
Very recent work (Stricker et al., in press) has shown
that direct reprogramming of the glioblastoma epigenome
restores developmental potential but does not eﬃciently
suppress proliferation [41]. This fundamental study uses
a reprogramming approach to convert glioblastoma into
immature teratoma.Pathology Research International 3
5.Conclusions
In conclusion, the cancer stem theory predicts that not all
tumour cells are equal. Although we cannot be certain about
the precise cell of origin of gliomas, we may have the ability
to control them to a certain degree using epigenetic means.
Thisrepresentsamajorconceptualadvanceintheﬁeld,butit
isstill contraversial.Majornewinsightsintocancerstemcells
will hopefully direct a new era of patient-speciﬁc combined
molecular therapies.
References
[ 1 ]K .R .H e s s ,K .R .B o g l i o ,a n dM .L .B o n d y ,“ A d u l tg l i o m a
incidence trends in theUnited States,1977–2000,”Cancer,v o l .
101, no. 10, pp. 2293–2299, 2004.
[2] K. M. Kurian, “Recent advances in glial tumours,” ANCR,v o l .
8, no. 6, pp. 24–26, 2009.
[3] P. Kleihues and W. K. Cavenee, “WHO Classiﬁcation of
Tumours of the Nervous System,” 2007.
[4] D. Bonnet and J. E. Dick, “Human acute myeloid leukaemia
is organized as a hierarchy that originates from a primitive
hemapoetic stem cell,” Nature Medicine, vol. 3, pp. 730–737,
1997.
[5] C. D. Stiles and D. H. Rowitch, “Glioma stem cells: a midterm
exam,” Neuron, vol. 58, no. 6, pp. 832–846, 2008.
[6] T.Reya,S.J.Morrison,M.F.Clarke,andI.L.Weissman,“Stem
cells, cancer, and cancer stem cells,” Nature, vol. 414,no. 6859,
pp. 105–111, 2001.
[ 7 ]B .T .T a n ,C .Y .P a r k ,L .E .A i l l e s ,a n dI .L .W e i s s m a n ,“ T h e
cancer stem cell hypothesis: a work in progress,” Laboratory
Investigation, vol. 86, no. 12, pp. 1203–1207, 2006.
[ 8 ]R .M c K a y ,“ S t e mc e l l si nt h ec e n t r a ln e r v o u ss y s t e m , ”Science,
vol. 276, no. 5309, pp. 66–71, 1997.
[ 9 ]S .M .P o l l a r d ,L .C o n t i ,Y .S u n ,D .G o ﬀredo, and A. Smith,
“Adherent neural stem (NS) cells from fetal and adult
forebrain,” Cerebral Cortex, vol. 16, pp. 112–120, 2006.
[10] N.Uchida,D.W.Buck,D.Heetal.,“Direct isolationofhuman
central nervous system stem cells,” Proceedings of the National
Academy of Sciencesof the United States of America, vol.97, no.
26, pp. 14720–14725, 2000.
[11] T. N. Ignatova, V. G. Kukekov, E. D. Laywell et al., “Human
cortical glial tumors contain neural stem-like cells expressing
astroglial and neuronal markers in vitro,” GLIA,v o l .3 9 ,n o .3 ,
pp. 193–206, 2002.
[12] R. Galli, E. Binda, U. Orfanelli et al., “Isolation and charac-
terisation of tumourigenic stem-like neural precursors from
human glioblastoma,” Cancer Research, vol. 64, pp. 7011–
7021, 2004.
[13] H. D. Hemmati, I. Nakano, J. A. Lazareﬀ et al., “Cancerous
stem cells can arise from pediatric brain tumors,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 100, no. 25, pp. 15178–15183, 2003.
[14] S. K. Singh, I. D. Clarke, M. Teraski et al., “Identiﬁcation of a
cancer a stem cell in human brain tumours ,” Cancer Research,
vol. 63, pp. 5821–5828, 2003.
[15] K. M. Joo, S. Y. Kim, X. Jin et al., “Clinical and biological
implications of CD133-positive and CD133-negative cells in
glioblastomas,” Laboratory Investigation,v o l .8 8 ,n o .8 ,p p .
808–815, 2008.
[16] M. D. Taylor, H. Poppleton, C. Fuller et al., “Radial glia cells
are candidate stem cells of ependymoma,” Cancer Cell,v o l .8 ,
no. 4, pp. 323–335, 2005.
[17] R. J. Gilbertson and J. N. Rich, “Making a tumour’s bed:
glioblastoma stem cells and the vascular niche,” Nature
Reviews Cancer, vol. 7, no. 10, pp. 733–736, 2007.
[18] T .S.Jac ques,A.S wales,M.J .Brzozowskietal.,“ C ombinations
of genetic mutations in the adult neural stem cell com-
partment determine brain tumour phenotypes,” The EMBO
Journal, vol. 29, pp. 222–235, 2010.
[19] T. G. Oliver and R. J. Wechsler-Reya, “Getting at the root and
stem of brain tumors,” Neuron, vol. 42, no. 6, pp. 885–888,
2004.
[20] N. Sanai, A. Alvarez-Buylla, and M. S. Berger, “Mechanisms
of disease: neural stem cells and the origin of gliomas,” New
England Journal of Medicine,vol.353,no.8,pp.811–822,2005.
[ 2 1 ]F .D o e t s c h ,I .C a i l l e ,D .A .L i m ,J .M .G a r c i a - V e r d u g o ,a n d
A. Alvarez-Buylla, “Subventricular zone astrocytes are neural
stem cells in the adult mammalian brain,” Cell, vol. 97, no. 6,
pp. 703–716, 1999.
[22] E. L. Jackson, J. M. Garcia-Verdugo, S. Gil-Perotin et al.,
“PDGFR alpha-positive B cells are neural stem cells in the
adult SVZ that form glioma-like growths in response to
increased PDGF signalling,” Neuron, vol. 51, no. 2, pp. 187–
199, 2006.
[23] H. Zheng, H. Ying, H. Yan et al., “p53 and Pten control neural
and glioma stem/progenitor cell renewal and diﬀerentiation,”
Nature, vol. 455, no. 7216, pp. 1129–1133, 2008.
[ 2 4 ]Y .Z h u ,F .G u i g n a r d ,D .Z h a oe ta l . ,“ E a r l yi n a c t i v a t i o no f
p53 tumorsuppressorgene cooperatingwithNF1 lossinduces
malignant astrocytoma,” Cancer Cell, vol. 8, pp. 119–130,
2005.
[ 2 5 ]E .C .H o l l a n d ,J .C e l e s t i n o ,C .D a i ,L .S c h a e f e r ,R .E .S a w a y a ,
and G. N. Fuller, “Combined activation of Ras and Akt in
neural progenitors induces glioblastoma formation in mice,”
Nature Genetics,vol. 25, no. 1, pp. 55–57, 2000.
[26] S. W. M. Bruggeman, D. Hulsman, E. Tanger et al., “Bmi1
controls tumor development in an Ink4a/Arf-independent
m a n n e ri nam o u s em o d e lf o rg l i o m a , ”Cancer Cell, vol. 12,
no. 4, pp. 328–341, 2007.
[27] S. Alcantara Llaguno, J. Chen, C. H. Kwon et al., “Malignant
astrocytomas originate from neural stem/progenitor cells in a
somatictumor suppressor mousemodel,” Cancer Cell, vol.15,
no. 1, pp. 45–56, 2009.
[ 2 8 ]Y .W a n g ,J .Y a n g ,H .Z h e n ge ta l . ,“ E x p r e s s i o no fm u t a n tp 5 3
proteins implicates a lineage relationship between neural stem
cells and malignant astrocytic glioma in a murine model,”
Cancer Cell, vol. 15, no. 6, pp. 514–526, 2009.
[ 2 9 ]R .M .B a c h o o ,E .A .M a h e r ,K .L .L i g o ne ta l . ,“ E p i d e r m a l
growthfactorreceptor andInk4a/Arf:convergentmechanisms
governing terminal diﬀerentiation and transformation along
the neural stem cell to astrocyte axis,” Cancer Cell,v o l .1 ,n o .
3, pp. 269–277, 2002.
[ 3 0 ]H .D i n g ,L .R o n c a r i ,P .S h a n n o ne ta l . ,“ A s t r o c y t e - s p e c i ﬁ c
expression of activated p21-ras results in malignant astro-
cytoma formation in a transgenic mouse model of human
gliomas,”Cancer Research, vol.61, no. 9, pp. 3826–3836,2001.
[31] E. C. Holland, W. P. Hively, V. Gallo, and H. E. Varmus,
“Modeling mutations in the G1 arrest pathway in human
gliomas: overexpression of CDK4 but not loss of INK4a-ARF
induces hyperploidy in cultured mouse astrocytes,” Genes and
Development, vol. 12, no. 23, pp. 3644–3649, 1998.
[32] L. Uhrbom, M. Kastemar, F. K. Johansson, B. Westermark,
and E. C. Holland, “Cell type-speciﬁc tumor suppression by
Ink4a and Arf in kras-induced mouse gliomagenesis,” Cancer
Research, vol. 65, no. 6, pp. 2065–2069, 2005.4 Pathology Research International
[ 3 3 ]A .X i a o ,C .Y i n ,C .Y a n g ,A .D iC r i s t o f a n o ,P .P .P a n d o l ﬁ ,
and T. Van Dyke, “Somatic induction of Pten loss in a
preclinical astrocytoma model reveals major roles in disease
progression and avenues for target discovery and validation,”
Cancer Research, vol. 65, no. 12, pp. 5172–5180, 2005.
[34] K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of
pluripotent stemcellsfromadulthumanﬁbroblastsbydeﬁned
factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007.
[ 3 5 ]J .S i l v a ,O .B a r r a n d o n ,J .N i c h o l s ,J .K a w a g u c h i ,T .W .
Theunissen, and A. Smith, “Promotion of reprogramming to
ground state pluripotency by signal inhibition,” PLoS Biology,
vol. 6, no. 10, Article ID e253, pp. 2237–2247, 2008.
[36] K. Woltjen, I. P. Michael, P. Mohseni et al., “piggyBac
transposition reprograms ﬁbroblasts to induced pluripotent
stem cells,” Nature, vol. 458, no. 7239, pp. 766–770, 2009.
[37] H. Zhou, S. Wu, J. Y. Joo et al., “Generation of induced
pluripotent stem cells using recombinant proteins,” Cell Stem
Cell, vol. 4, pp. 381–384, 2009.
[38] J. Yu, K. Hu, K. Smuga-Otto et al., “Human induced
pluripotent stem cells free of vector and transgene sequences,”
Science, vol. 324, no. 5928, pp. 797–801, 2009.
[39] S. G. M. Piccirillo, B. A. Reynolds, N. Zanetti et al., “Bone
morphogenetic proteins inhibit the tumorigenic potential of
human brain tumour-initiating cells,” Nature, vol. 444, no.
7120, pp. 761–765, 2006.
[40] I. Nakano, K. Saigusa, and H. I. Kornblum, “BMPing oﬀ
glioma stem cells,” Cancer Cell, vol. 13, no. 1, pp. 3–4, 2008.
[41] S.H.Stricker,A.Feber, K.M.Kurianet al.,“Direct reprogram-
ming of the glioblastoma epigenome restores developmental
potential but does not eﬃciently suppress proliferation,” Cell
Stem Cell. In press.